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Andrea Niedermeier1,4, Nickolai Talanin1,4, Eun Joo Chung2, Ryan E. Sells1, Debra L. Borris1,
Jan M. Orenstein3, Jane B. Trepel2 and Andrew Blauvelt1
Kaposi’s sarcoma-associated herpesvirus (KSHV) latently infects tumor cells in patients with Kaposi’s sarcoma
and primary effusion lymphoma (PEL). The purpose of this study was to determine whether histone deacetylase
inhibitors (HDAI) could induce apoptosis, with minimal viral replication, in cells latently infected with KSHV.
Four HDAI (depsipeptide, suberoylanilide hydroxamic acid, MS-275, and trichostatin A) were studied in two PEL
B cell lines (BCBL-1, BC-3). As expected, histone hyperacetylation was readily induced in all PEL cells exposed to
HDAI. HDAI also triggered KSHV reactivation in a time- and dose-dependent manner. Flow cytometric and
transmission electron microscopic studies, however, revealed that reactivation occurred in only a minor
percentage (3–14%) of treated cells. Importantly, and in contrast to viral reactivation, HDAI induced apoptotic
cell death in a dose-dependent manner in a large percentage (up to 90%) of KSHV-infected cells. In summary, all
four HDAI tested induced histone hyperacetylation in all cells, KSHV reactivation in a minority of cells, and
apoptotic cell death in a majority of cells latently infected with KSHV. These findings suggest that HDAI may be a
therapeutic option for patients with KSHV-mediated diseases by rendering cells infected with KSHV susceptible
to apoptosis.
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INTRODUCTION
Gene transcription is regulated by acetylation status of core
nucleosomal histones, which is determined by the opposing
activities of histone acetyltransferases and histone deacetyl-
ases (Grunstein, 1997; Kornberg and Lorch, 1999; Kouzarides,
1999). Specifically, nucleosomes containing histones with
relatively low levels of acetylated lysine residues result
in decreased or silenced gene expression. Conversely,
conditions that favor lysine acetylation on core histone
proteins often induce gene transcription. Mechanistically,
deacetylation of lysine residues in tail regions of histones is
presumed to inhibit transcription by increasing the positive
charge of histones, enhancing bonds to negatively charged
DNA, condensing the structures of nucleosomes, and thereby
blocking the access of target DNA promoter regions to
transcription factors, regulatory complexes, and RNA poly-
merase. By contrast, conditions that favor histone hyperace-
tylation, such as treatment of cells with histone deacetylase
inhibitors (HDAI), lead to weaker histone–DNA bonds, looser
nucleosomal structures, and more active gene transcription
(Weidle and Grossmann, 2000; Marks et al., 2001).
This paradigm has been useful for understanding certain
aspects of cancer biology. Many cancers and cancer cell lines
exhibit transcriptional repression, or silencing, of selective
genes critically involved in tumor suppressor, proapoptotic,
and differentiation pathways (Muraoka et al., 1996; Grignani
et al., 1998; Lin et al., 1998). This type of selective silencing
can lead to unregulated growth of relatively undifferentiated
cells, thus tipping normal cellular processes in favor of
carcinogenesis. In hopes of ‘‘normalizing’’ transcription of
silenced genes, investigators have explored the use of HDAI
as potential therapeutic agents in cancer (Marks et al., 2001;
Piekarz and Bates, 2004). There are several structural classes
of HDAI, including short-chain fatty acids (e.g., butyrates)
(Newmark et al., 1994), hydroxamic acids (e.g., trichostatin A
(TSA) and suberoylanilide hydroxamic acid (SAHA)) (Richon
et al., 1998), cyclic tetrapeptides (e.g., trapoxin A) (Kijima
et al., 1993), cyclic peptides (e.g., depsipeptide) (Nakajima
et al., 1998), and benzamides (e.g., MS-275) (Saito et al.,
1999). These drugs induce transcription of silenced genes and
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promote apoptosis in many cancer cell lines both in vitro and
in vivo (Weidle and Grossmann, 2000; Marks et al., 2001).
Furthermore, clinical studies using HDAI in cancer patients
have shown some promising results, especially with more
recently developed drugs (Gore and Carducci, 2000; Piekarz
et al., 2001; Sandor et al., 2002; Kelly et al., 2003), making
cancer therapy with HDAI an exciting area of active clinical
investigation.
Interestingly, cells that are chronically infected with
certain viruses resemble cancer cells in that they often
escape normal immune surveillance. In fact, chronic infec-
tions by a number of viruses can lead to the development of
cancers, as seen with hepatitis B and C viruses, human
papillomaviruses, human T-lymphotropic virus-1, Epstein–-
Barr virus, and Kaposi’s sarcoma-associated herpesvirus
(KSHV). Many cells infected by these viruses, like cancer
cells, demonstrate selective inactivation or silencing of genes
critically involved in immune surveillance (Block et al., 2003;
Fehrmann and Laimins, 2003; Matsuoka, 2003; Moore and
Chang, 2003; Young and Murray, 2003). In particular, KSHV,
which is associated with Kaposi’s sarcoma, primary effusion
lymphoma (PEL), and the plasmablastic variant of multi-
centric Castleman’s disease (Moore and Chang, 2003),
encodes for latency-associated nuclear antigen, which has
been shown to silence gene transcription in KSHV-infected
cells (Schwam et al., 2000; Garber et al., 2002; Watanabe
et al., 2003).
As observed in cancer cells, HDAI have been shown to
activate transcription in cells with virus-induced silencing of
gene expression (Kiernan et al., 1999; Zhao et al., 1999;
Meier, 2001; Merezak et al., 2002; Mizutani et al., 2002;
Subramanian et al., 2002). For KSHV, it is well established
that sodium butyrate, an older and less clinically useful
HDAI, activates KSHV from latency (Miller et al.,
1996; Zoeteweij et al., 1999). This effect is believed to be
secondary to chromatin remodeling and activation of the
KSHV ORF50 promoter, which is critical for KSHV
reactivation from latency (Lu et al., 2003). In this report, we
studied in detail the biologic effects caused by exposing
KSHV-infected cells to several newer and more clinically
relevant HDAI. We found that these HDAI concomitantly
induced relatively low levels of viral reactivation and
relatively high levels of apoptosis in cells chronically
infected with KSHV. These findings suggest that HDAI may
be useful therapeutic options for patients with KSHV-
mediated diseases.
RESULTS
HDAI induce acetylation of histone H3 in KSHV-infected cells
BCBL-1 incubated with each of the four HDAI for 2 days
were collected, cytocentrifuged onto glass slides, fixed, and
labeled with anti-acetylated histone H3 polyclonal anti-
bodies. As expected based upon their known mechanism of
action, all HDAI tested induced acetylation of histone H3.
Higher doses of each HDAI induced more acetylation than
10-fold lower doses for each HDAI (Figure 1; data not
shown). These results are consistent with those obtained in
other cell types being treated with HDAI.
HDAI induce lytic-cycle mRNA expression in cells latently
infected with KSHV
To determine whether HDAI induce triggering of the lytic
cycle in cells latently infected with KSHV, BCBL-1 were
assessed for KSHV lytic-cycle mRNA expression using real-
time reverse transcription-PCR. We chose three KSHV genes
specific for the lytic cycle to study: one immediate–early lytic-
cycle gene (ORF50), one early lytic cyle gene (ORF59), and
one late lytic-cycle gene (ORFK8.1). All four HDAI tested
stimulated expression of lytic-cycle mRNA, and each of
the three independent experiments yielded similar results
(Figure 2). Furthermore, the kinetics of mRNA expression for
each of the three genes assessed was internally consistent
with the known function of each of these three genes.
Specifically, peak expression of ORF50 and ORF59 mRNA,
which are both expressed during the early half of the KSHV
lytic cycle, was observed at the 1-day time point following
incubation with depsipeptide, SAHA, and TSA, whereas peak
expression occurred slightly later (at the 2-day time point)
following stimulation with MS-275 (Figure 2). In contrast, in
most of the experiments and with most of the HDAI, peak
mRNA expression of ORFK8.1, a gene expressed in the latter
half of the lytic cycle, occurred 3 days following incubation
with HDAI (Figure 2).
HDAI induce lytic-cycle protein expression in a dose- and time-
dependent manner in a minor percentage of cells latently
infected with KSHV
To determine whether increases in lytic-cycle mRNA expres-
sion corresponded to increases in lytic-cyle protein express-
sion, we utilized a high-throughput flow cytometry-based
assay that had been established within our laboratory
(Zoeteweij et al., 1999). Specifically, we labeled and
quantified cells expressing two lytic-cycle proteins: PF-8
(encoded by ORF59) and gpK8.1 (encoded by ORFK8.1). All
four HDAI tested induced expression of these proteins in a
dose- and time-dependent manner (Figure 3). As well, protein
expression was observed in two different KSHV-infected cells
lines, BCBL-1 (Figure 3a and c) and BC-3 (Figure 3b). PF-8
a b
Figure 1. HDAI induce acetylation of histone H3 in KSHV-infected cells.
BCBL-1 cells were incubated (a) without or (b) with 4 nM of depsipeptide for
2 days, collected, spun onto glass slides, and incubated with antiacetylated
histone H3 polyclonal antibody and Cy3-conjugated secondary antibody.
Similar levels of acetylation results were observed when cells were incubated
with 250 nM of SAHA, 200 nM of MS-275, or 33 nM of TSA (data not shown).
Lower levels of acetylation were observed with 10-fold lower doses of each
HDAI (data not shown). Results shown are representative of three
independent experiments. Bar¼ 6 mm.
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production in response to SAHA and TSA reached its
maximum, with up to 14 and 4% positive cells, respectively,
2 days following stimulation by HDAI, whereas response to
depsipeptide and MS-275 was slower, peaking at the 3-day
time point, with up to 5 and 11% positive cells, respectively.
Induction of gpK8.1 followed a similar pattern, although the
number of positive cells induced by each HDAI was smaller
compared to those expressing PF-8. In general, higher doses
of HDAI increased the number of positive cells, but also
increased cellular toxicity (Figure 3 and data not shown).
HDAI induce production of virions in a minor percentage of
cells latently infected with KSHV
To determine whether HDAI could induce complete activa-
tion of the KSHV lytic cycle, BCBL-1 cells were stimulated for
2 days by HDAI, processed for electron microscopy, and
evaluated for evidence of KSHV virions by an electron
microscopist blinded to the culture conditions. For all four
HDAI (at the doses tested), 3–7% of cells demonstrated
ultrastructural features characteristic of KSHV reactivation
(Figure 4; data not shown). Specifically, spherical nuclei with
variably staining nuclear material were observed, the central
portion of which contained fine granular-fibrillar material,
sometimes with electron-dense margins (Figure 4a). In
addition, nuclei with ‘‘starburst’’ intranuclear inclusions with
dense central granules were readily detected (Figure 4a).
Nucleocapsids, concentrated in the marginated nuclear
material (Figure 4a), were either empty or contained a central
membranous structure without or with electron-dense mate-
rial (Figure 4b). The latter finding is characteristic for KSHV
virions. These ultrastructural features were either not ob-
served or occurred rarely (in less than 1% of cells) when
control cells were incubated without HDAI (data not shown).
In one of the two electron microscopy experiments, portions
of BCBL-1 were concomitantly evaluated for lytic-cycle
protein expression by flow cytometry. In this experiment,
there was a good correlation between the percentage of cells
demonstrating lytic-cycle ultrastructural changes by elecron
microscopy and the percentage of cells expressing the lytic-
cycle protein PF-8 by flow cytometry: 6 and 7.4% for
depsipeptide, 4 and 2.7% for SAHA, 4 and 7.2% for MS-275,
and 3 and 2.8% for TSA (data not shown).
HDAI induce early apoptotic cell death and late-phase cell
death in a dose-dependent manner in a majority of KSHV-
infected cells
To determine whether HDAI-induced KSHV reactivation
could lead to early apoptotic cell death and late-phase cell
death, HDAI-treated BCBL-1 cells were assessed using two
different methods: (1) flow cytometry to detect DNA strand
breaks (TUNEL positivity), a sign of apoptosis and (2) flow
cytometry to detect cell surface phosphatidylserine (Annexin
V positivity) and 7-AAD uptake, indications of early apoptotic
cell death and late-phase cell death, respectively. Forty hours
following treatment with relatively high doses of HDAI,
70–90% of cells were TUNEL positive (Figure 5). Similarly, as
positive controls, cells treated with camptothecin, an
inhibitor of DNA topoisomerase I, were apoptotic (80%
TUNEL positive) (Figure 5).
Next, we concomitantly assessed both early apoptosis and
late-phase cellular death in HDAI-treated cells using double
labeling for Annexin V and 7-AAD uptake. One time point
was chosen (day 1) for these experiments, whereas a variety
of HDAI doses were studied. Earlier time points (6 and
12 hours) did not reveal sufficient numbers of dying cells to
study, whereas later time points (48 and 96 hours) revealed a
predominance of 7-AAD-positive cells (data not shown). All
HDAI tested induced early apoptotic cell death in BCBL-1 at
24 hours, as demonstrated by an increase in Annexin
V-positive and 7-AAD-negative cells (Figure 6). All HDAI
tested also induced late-phase cell death, as demonstrated by
a decrease in 7-AAD-negative cells (Figure 6). Not surpris-
ingly, both early apoptosis and late-phase cell death
increased with increasing HDAI concentration (Figure 6).
DISCUSSION
In this study, we found that a number of clinically useful
HDAI induced KSHV-infected cells to undergo apoptosis in a
dose- and time-dependent manner. Importantly, apoptosis of
these cells was associated with viral reactivation in only a
small subset of cells. These findings suggest that HDAI may
be a useful therapeutic class of drugs to treat Kaposi’s
sarcoma and other KSHV-mediated diseases. This type of
treatment would be aimed at ‘‘flushing out’’ cells chronically
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Figure 2. HDAI induce lytic-cycle mRNA expression in cells latently
infected with KSHV. BCBL-1 cells were incubated with or without the
indicated HDAI at the indicated doses for 1, 2, or 3 days. Cells were
collected, total RNA was extracted, RNA was reverse transcribed to cDNA,
and then real-time reverse transcription-PCR was performed using primer
pairs specific for KSHV immediate–early lytic cycle (ORF50), early lytic cycle
(ORF59), and late lytic-cycle (ORFK8.1) mRNA. For each sample, viral mRNA
levels were normalized to GAPDH mRNA levels and fold increases were
calculated using mRNA levels in unstimulated cells as a comparison.
Results from three independent experiments are shown as individual lines
in the graphs.
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infected with KSHV. Because viral reactivation could also
occur, HDAI treatment of Kaposi’s sarcoma could be
administered with concomitant antiherpesviral drugs (e.g.,
valganciclovir) to prevent viral replication and infection of
new cells. This strategy would be analogous to the approach
taken by HIV researchers who utilize IL-2, to activate virus
from latently infected reservoirs, in combination with highly
active antiretroviral therapy, to block viral replication (Sereti
et al., 2004).
Recently, such a combination drug strategy with HDAI
and antiherpesviral drugs was suggested by Offermann and
colleagues (Shaw et al., 2000; Klass et al., 2005). They used
the anti-seizure medication valproic acid, which is able to
inhibit histone deacetylation, in combination with ganciclo-
vir or foscarnet to induce apoptosis and prevent viral
replication in KSHV-infected PEL cells. Our findings reported
here using newer HDAI (depsipeptide, SAHA, MS-275, and
TSA) are consistent with these recent studies using valproic
acid, and older studies using butyrate (Miller et al., 1996;
Zoeteweij et al., 1999). Our findings add the biologically and
clinically important caveat that the proapoptotic effects of
HDAI far surpass their ability to induce KSHV replication.
Taken together, the results of these in vitro studies support
the concept of ‘‘flush out’’ therapy as a viable strategy
for treatment, and possibly cure, of chronic herpesviral
infections.
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Figure 3. HDAI induce lytic-cycle protein expression in a dose- and time-dependent manner in a minor percentage of cells latently infected with KSHV.
(a) BCBL-1 or (b) BC-3 cells were incubated with or without the indicated HDAI at the indicated doses for 2 days. Cells were collected, fixed, and permeabilized
to allow for labeling of intracellular proteins, and incubated with either anti-PF8 or anti-gpK8.1 mAbs. PF-8 and gpK8.1 are KSHV early lytic cycle and late
lytic-cycle proteins, respectively, encoded by ORF59 and ORFK8.1, respectively. Flow cytometry was used to quantify the number of live cells expressing each
intracellular KSHV lytic-cycle protein. (a) and (b) show results from single representative experiments at 2 days, whereas (c) shows a summary of five separate
dose- and time-dependent experiments using BCBL-1 cells (demonstrating means and standard deviations). Open circles¼ 2 days; filled circles¼ 3 days.
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Clinically, studies in cancer patients using older HDAI
compounds have been limited by their short half-life, low
antitumor activity (e.g., butyrate), and non-specific toxicity
(e.g., depudecin) (Novogrodsky et al., 1983; Miller et al.,
1987; Kwon et al., 1998). More recently, however, newer
agents in this class of drugs (MS-275, SAHA, and depsipep-
tide) appear to target tumors more selectively and appear to
be less toxic (Sandor et al., 2002; Kelly et al., 2003; Byrd
et al., 2005). Results from published and ongoing phase I, II,
and III studies suggest that HDAI have significant activity in
lymphoid malignancies (Piekarz and Bates, 2004). These
clinical results would be consistent with the HDAI-mediated
proapoptotic effects we demonstrated in PEL cells in vitro, as
well as consistent with many other studies that demonstrated
marked apoptotic killing of cancer cells of lymphoid origin in
vitro by HDAI (Inoue et al., 2004; Maggio et al., 2004;
Roychowdhury et al., 2004). Thus, we believe it is likely that
patients with PEL, a rare non-Hodgkin’s B-cell lymphoma,
would respond to HDAI, which is encouraging given that PEL
has an extremely poor prognosis (Knowles, 2003).
Lastly, the use of HDAI in patients with one of the other
two KSHV-associated diseases, either Kaposi’s sarcoma or
multicentric Castlemen’s disease, should also be considered.
It is possible, however, that HDAI may not be as effective in
inducing apoptosis in these cells when compared to KSHV-
infected B cells. Alternatively, KSHV infection itself, inde-
pendent of cell type, may render cells susceptible to killing by
HDAI. Additional studies are needed to explore further the
effects of HDAI on KSHV-infected endothelial cells.
MATERIALS AND METHODS
Cell lines and reagents
KSHV-positive and Epstein–Barr virus-negative PEL cell lines BCBL-1
(Renne et al., 1996) (National Institutes of Health AIDS Research and
Reagent Program, Rockville, MD) and BC-3 (Arvanitakis et al., 1996)
(American Type Culture Collection, Rockville, MD) were grown in
RPMI 1640 medium (Gibco BRL, Gaithersburg, MD) containing 10%
fetal calf serum, 2 mM L-glutamine, 100 U/ml of penicillin, 100 mg/ml
of streptomycin, 10 mM HEPES (all from Gibco), and 5 105
2-mercaptoethanol (Sigma Chemical Co., St. Louis, MO). Cells were
incubated with the following HDAI: depsipeptide (National Cancer
Institute Drug Synthesis and Chemistry Branch, Bethesda, MD),
SAHA (Alexis Biochemicals, San Diego, CA), MS-275 (EMD
Biosciences, San Diego, CA), and TSA (Sigma).
Detection of acetylated histone H3
BCBL-1 cells were cultured in the presence or absence of an HDAI
compound (0.4 or 4 nM depsipeptide, 25 or 250 nM SAHA, 20 or
200 nM MS-275, or 3.3 or 33 nM TSA). Cells were harvested on day 2,
spun onto glass slides by cytocentrifugation (Cytospin 2, Thermo
a b
Figure 4. HDAI induce production of virions in a minor percentage of
cells latently infected with KSHV. (a) Low and (b) high-power electron
micrographs of BCBL-1 cells stimulated for 2 days by 4 nM of depsipeptide.
(a) In 3–7% of cells, nuclei showed ‘‘starburst’’ intranuclear inclusions with
dense central granules. Nucleocapsids, seen concentrated in the marginated
nuclear material (a), were either empty or contained a central membranous
structure without or with electron-dense material (b). The latter finding is
characteristic for KSHV virions. Similar results were observed when cells were
incubated with 250 nM of SAHA, 200 nM of MS-275, or 33 nM of TSA, whereas
no virions were observed when control cells were incubated without HDAI
(data not shown). Results shown are representative of two independent
experiments. Bar¼ (a) 600 nm; (b) 150 nm.
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Figure 5. HDAI induce apoptosis (TUNEL positive cells) in a majority of
KSHV-infected cells. BCBL-1 cells were incubated without (open graphs) or
with the indicated HDAI at the indicated concentrations (solid graphs) for
40 hours and assessed for DNA strand breaks (TUNEL positivity) by flow
cytometry. As a positive control, apoptosis was induced in BCBL-1 cells by
camptothecin. (a) Shows results from a single representative experiment,
whereas (b) shows a summary of three separate experiments (demonstrating
means and standard deviations).
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Shandon, Pittsburgh, PA), fixed in 95% ethanol with 5% glacial
acetic acid for 1 minute, and permeabilized with 0.2% Triton X-100
for 10 minutes at room temperature. Non-specific binding sites were
blocked by incubating cells with 1% (w/v) BSA in phosphate-
buffered saline (PBS) for 1 hour at 41C, and then cells were incubated
with polyclonal rabbit anti-acetylated histone H3 antibodies
(Upstate Biotechnology, Waltham, MA) at 10 mg/ml for 1 hour at
41C, washed two times for 2 minutes in PBS, and incubated with
Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA) at 10 mg/ml for 1 hour at 41C. After
incubation, cells were washed with PBS, rinsed with water, air-dried,
mounted using SlowFades (Molecular Probes, Eugene, OR), and
examined using a Zeiss Axiophot microscope interfaced with a CCD
camera (Optronics Engineering, Goleta, CA). The experiments were
performed three times.
Quantification of KSHV lytic-cycle mRNA levels
BCBL-1 cells were seeded into T-25 culture flasks (2.5 105 cells/ml)
and grown for 1 day. Cells were then cultured for an additional 1, 2,
or 3 days in the presence or absence of an HDAI compound (4 nM
depsipeptide, 250 nM SAHA, 200 nM MS-275, or 33 nM TSA). Cells
were harvested and total RNA was isolated using RNeasys kits
(Qiagen, Valencia, CA) according to the manufacturer’s protocol.
Fifty nanograms of total RNA was reverse transcribed to cDNA and
used for each PCR reaction. Quantification of KSHV lytic-gene
mRNA transcripts was performed by real-time fluorescence detec-
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Figure 6. HDAI induce early apoptotic cell death (Annexin V-positive cells) and late-phase cell death (7-AAD positive cells) in a dose-dependent manner in
a majority of KSHV-infected cells. BCBL-1 cells were incubated with or without the indicated HDAI at the indicated concentrations for 1 day and assessed
for early apoptotic cell death (Annexin V labeling of cell surface phosphatidylserine) and late-phase cell death (7-AAD uptake) by flow cytometry. (a) Shows
results from a single representative dose–response experiment. (b) A summary of three separate experiments (demonstrating means and standard deviations)
shows that the number of live cells decreased and the number of apoptotic cells increased with increasing HDAI concentration. Solid bars¼ 7-AAD-negative
(live) cells, dotted bars¼ 7-AAD-negative and Annexin V-positive (apoptotic) cells.
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tion using SYBRs Green and the ABI PRISMs 7700 DNA Sequence
Detector (all from Applied Biosystems, Foster City, CA) as per the
manufacturer’s protocol. The following oligonucleotide primers
were used for real-time reverse transcription-PCR: (a) ORF50: sense
50-TTT TCG TGC CTC TCG AAT GA-30 and antisense 50-TCT GCG
CAT GGC ACG TT-30; (b) ORF59: sense 50-CGT CGG TAG CGG
CTT CA-3 and antisense 50-GGC TAT GCC AGC GTC GAG TA-30;
(c) ORFK8.1: sense 50-TTC CAC ACA GAT TCG CAC AGA-30 and
antisense 50-GGC ACG CCA CCA GAC AA-30; (d) GAPDH sense
50- CGT GTT CCT ACC CCC AA TGT-30 and antisense 50-TGT CAT
CAT ACT TGG CAG GTT TCT-30. Primers were designed using the
computer program Primer Express (Applied Biosystems) and were
synthesized by Invitrogen Corp. (Carlsbad, CA). For each experi-
ment, a threshold cycle value, or Ct, was calculated for each gene by
determining the point at which PCR product fluorescence exceeded
a threshold limit. Relative expression level of each gene compared to
GAPDH expression was calculated as 2[(Ct of gene)(Ct of GAPDH)].
After normalization to GAPDH expression in this manner, fold
differences in gene expression between stimulated versus non-
stimulated cells were assessed. Negative control PCR tubes
lacking either reverse transcriptase or template cDNA were always
included in each experiment. The experiments were performed
three times.
Quantification of KSHV lytic-cycle protein levels
BCBL-1 or BC-3 were seeded into T-25 culture flasks and incubated
with or without HDAI as described above. HDAI dose ranges were
as follows: depsipeptide (0.4–4 nM), SAHA (25–500 nM), MS-275
(25–500 nM), and TSA (16.5–82.5 nM). Cells were harvested 2 or 3
days later, washed, resuspended in PBS containing 0.1% (w/v) BSA
and 0.05% (w/v) NaN3, and transferred to V-bottom 96-well plates
(3 105 cells/well). Dead cells were then stained with Dead Red
(Live/Dead kit; Molecular Probes, Eugene, OR) for 20 minutes at 41C.
Cells were then washed, incubated with Cytofix/Cytoperm kit
(Pharmingen, San Diego, CA), washed again with PermWash buffer
(Pharmingen), and resuspended for 30 minutes at 41C in PermWash
buffer containing mouse mAbs (1 mg/ml) directed against PF-8
(Advanced Biotechnologies, Inc., Columbia, MD) or gpK8.1 (a kind
gift of Bagher Forghani, California Department of Health Sciences,
Berkeley, CA). Cells were then washed, incubated for 30 minutes at
41C with FITC-conjugated goat anti-mouse IgG (Caltag Laboratories,
Burlingame, CA), washed again, resuspended in PBS containing
0.1% (w/v) BSA and 0.05% (w/v) NaN3, and analyzed using a
FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
Dead cells were identified by dead red fluorescence and excluded
from all analyses. Percentages of live cells expressing either PF-8 or
gpK8.1 were calculated for each experiment, and each experiment
was performed on five separate occasions.
Detection and quantification of KSHV virions
BCBL-1 cells were cultured as described above in the presence or
absence of an HDAI compound (4 nM of depsipeptide, 250 nM of
SAHA, 200 nM of MS-275, or 16.5 nM of TSA). Cells were harvested
2 days later, fixed overnight in neutral buffered 2.5% (v/v)
glutaraldehyde, and then mixed and pelleted in warm agar, which
was then cooled overnight to harden. Cells were then post-fixed in
1% OsO4, dehydrated in graded ethanol–propylene oxide, and
embedded in Spurr’s epoxy. Semithin 1mm plastic sections were
stained with methylene blue, azure II, and basic fuchsin for light
microscopic selection of blocks for thinning. Thin sections were
stained with uranyl acetate and lead citrate and examined on a Zeiss
EM10 electron microscope at 60 kV. At least 200 cells in each
sample were assessed for the presence of virions. Importantly, the
electron microscopist was blinded regarding the type of cellular
stimulation. The experiments were performed two times.
Detection and quantification of apoptosis
BCBL-1 cells were cultured as described above in the presence or
absence of an HDAI compound (40 nM of depsipeptide, 750 nM of
MS-275, 1.5 mM of SAHA, or 330 nM of TSA 330 nM). Cells treated
with camptothecin (Sigma), an inhibitor of DNA topoisomerase I
known to induce apoptosis, were used as positive controls. After
40 hours, apoptosis was quantified using the In Situ Cell Death
Detection Kit, Fluorescein (Roche, Indianapolis, IN) according to the
manufacturer’s protocol. Briefly, cells were washed, and fixed with
freshly prepared 4% paraformaldehyde for 60 minutes at 151C with
agitation. Cells were then washed, permeabilized for 2 minutes on
ice and 8 minutes at 221C with freshly prepared 0.1% Triton X-100
(Sigma) in 0.1% sodium citrate (Sigma), washed again, and
incubated with the TUNEL reaction mixture covered and in the
dark for 60 minutes at 371C. Cells were then washed and
analyzed by flow cytometry. Three independent experiments were
performed.
For concomitant detection and quantification of apoptosis and
cell death, BCBL-1 cells were cultured as described above in the
presence or absence of an HDAI compound (0.4, 4, or 40 mM of
depsipeptide; 50, 250, or 500 nM of MS-275; 100, 750, or 1500 nM of
SAHA; or 50, 165, or 330 nM of TSA). After 1 day, cells were
stained with the Annexin V/7-AAD Apoptosis Detection Kit I
(Pharmingen) according to the manufacturer’s protocol. Cells were
analyzed by flow cytometry. Three independent experiments were
performed.
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